MyFinsight
Home
Blog
About
Contact
Download
Download image
Stock-based compensation
expense
$993,700K
(1.11%↑ Y/Y)
Increase in accounts
payable, accrued...
$736,800K
(0.23%↑ Y/Y)
Depreciation and
amortization
$543,700K
(12.59%↑ Y/Y)
Decrease (increase) in
accounts receivable
-$498,100K
(-189.91%↓ Y/Y)
Other, net
-$135,500K
(-476.60%↓ Y/Y)
Net income
$4,504,900K
(2.09%↑ Y/Y)
Total adjustments
$474,000K
(5900.00%↑ Y/Y)
Canceled cashflow
$2,433,800K
Net cash provided by
operating activities
$4,978,900K
(12.63%↑ Y/Y)
Effect of exchange rate
changes on cash, cash...
$300K
(142.86%↑ Y/Y)
(gains) losses on
marketable and other...
$946,100K
(699.75%↑ Y/Y)
Deferred income taxes
$785,400K
(3.71%↑ Y/Y)
Increase in prepaid
expenses and other assets
$375,300K
(-7.90%↓ Y/Y)
Increase in inventories
$275,300K
(-55.58%↓ Y/Y)
(decrease) increase in
deferred revenue
-$51,700K
(-122.70%↓ Y/Y)
Net increase
(decrease) in cash, cash...
$634,700K
(355.10%↑ Y/Y)
Canceled cashflow
$4,344,500K
Proceeds from issuance of
common stock
$635,900K
(-56.60%↓ Y/Y)
Sales or maturities of
marketable and other...
$11,546,200K
(-23.17%↓ Y/Y)
Net cash used in
financing activities
-$3,715,400K
(-68.84%↓ Y/Y)
Net cash used in
investing activities
-$629,100K
(74.51%↑ Y/Y)
Canceled cashflow
$635,900K
Canceled cashflow
$11,546,200K
Repurchases of common stock
$3,438,600K
(32.09%↑ Y/Y)
Payments in connection
with common stock...
$532,100K
(-48.29%↓ Y/Y)
Purchases of marketable
and other...
$10,958,300K
(-34.06%↓ Y/Y)
Dividends paid
$370,300K
Other
-$10,300K
(69.16%↑ Y/Y)
Capital expenditures
$898,400K
(18.85%↑ Y/Y)
Payments for intangible
assets
$315,300K
(150.84%↑ Y/Y)
Acquisitions, net of cash
acquired
$3,300K
(-80.00%↓ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)